---
title: "Pharma Company Claims to Find Part of COVID-Fighting Cocktail"
description: "Therapeutics firm Sorrento claims to have found the first ingredient for its \"cocktail\" of antibodies that could protect against the coronavirus."
date: "2020-05-15"
modified: "2020-05-15"
authors:
  - name: "Victor Tangermann"
    job_title: "Senior Editor"
    link: "https://futurism.com/authors/victor"
url: "https://futurism.com/neoscope/pharma-part-covid-fighting-cocktail"
categories:
  - "Developments"
  - "Health & Medicine"
tags:
  - "coronavirus"
  - "covid19"
  - "vaccine"
---

# Pharma Company Claims to Find Part of COVID-Fighting Cocktail

![Therapeutics firm Sorrento claims to have found the first ingredient for its "cocktail" of antibodies that could protect against the coronavirus.](<https://futurism.com/wp-content/uploads/2020/05/company-first-ingredient-covid-fighting-cocktail.jpg>)
*\<em\>Image: Victor Tangermann\</em\>*

Pharmaceutical firm Sorrento Therapeutics claims to have found the first ingredient for a "cocktail" of antibodies that could be used to act as a "protective shield" against the coronavirus that causes COVID-19.

In [an announcement](<https://www.prnewswire.com/news-releases/sti-1499-a-potent-anti-sars-cov-2-antibody-demonstrates-ability-to-completely-inhibit-in-vitro-virus-infection-in-preclinical-studies-301059779.html>), the company said it had found a new antibody, called STI-1499, that was able to provide "100% inhibition of SARS-CoV-2 virus infection of healthy cells after four days incubation."

"Our STI-1499 antibody shows exceptional therapeutic potential and could potentially save lives following receipt of necessary regulatory approvals," Henry Ji, Chairman and CEO of Sorrento, said in the statement.

The identified antibody was shown to be effective in a not-yet-peer-reviewed preclinical study, and has not been tested in humans.

In other words, the research is still early-stage, and any implications should be taken with a grain of salt — particularly when a publicly traded pharmaceutic company has plenty to gain from such an announcement. To wit, Sorrento's shares [skyrocketed 244 percent](<https://markets.businessinsider.com/news/stocks/sorrento-therapeutics-stock-price-surges-covid-19-drug-development-claim-2020-5-1029207624>) today as a result.

The antibody stood out for being able to block interactions of the SARS-CoV-2's "spike" protein, which it uses to invade human cells. Researchers have been studying this protein to [develop a vaccine](<https://futurism.com/neoscope/good-news-human-body-builds-healthy-immune-response-to-covid>).

Sorrento is hoping to come up with a number of different antibodies to mix into a cocktail with the flashy — and copyrighted — name COVID-SHIELD, which would ensure patients are fully protected against the virus and its future mutations. The company is also looking at developing a standalone STI-1499 therapy as well.

Futurism [previously reported](<https://futurism.com/neoscope/doctors-cloned-covid-patients-antibodies-treatments>) on Sorrento teaming up with doctors and medical researchers at the Mount Sinai Health System earlier this month to clone and mass-produce the antibody cocktail.

"A vaccine takes time to generate immunity and not everyone will respond to a vaccine, especially the elderly and immune-compromised patients," Ji told Futurism at the time. "A neutralizing antibody cocktail bypassed the need for a patient to respond to a vaccine and gives instant immunity upon injection."

Sorrento is hopeful about its new product and is already looking at ramping up production, from about 200,000 doses per month to eventually a million doses a month.

It's also already in discussion with regulators to expedite its development.

## Author
I've been at Futurism since 2017, where my role has evolved to encompass design, writing, and increasingly editing. I've always been fascinated by space exploration and advanced transportation, which I've leaned into by interviewing luminaries in those fields while closely following the dimensions of policy and regulation that allow next-generation projects to succeed -- or, sometimes, to fail. I'm also keenly interested in the effects of generative AI on society, policies, and democratic institutions, as well as clean energy, physics and biology, and the vagaries of tech leadership. My work for Futurism has been cited by publications including Ars Technica, Gizmodo, PC Magazine, Jalopnik, Fox News, and the New York Post. I spent my childhood living in locations including Manila, the Philippines, and Geneva, Switzerland, attended McGill University, and now live in Toronto, Canada. Before Futurism I worked at AskMen and a small photography studio. In my free time, I'm an avid gardener, foodie, and craft beer lover, as well as a maker of artisanal hot pepper sauces. I have a magnificent dog named Freida.

### Author social links  
[Bluesky](<https://bsky.app/profile/vtanger.bsky.social>)